Prolor Biotech reported positive results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults. The findings show that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone (hGH), and further validates the dosing regimen for the company’s planned Phase III trial. In the Phase II clinical trial, hGH-CTP was administered to growth hormone deficient adults for a period of four weeks.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Satellites To Seek Out Underground Reserves Of Lithium
August 16, 2022

Israel To Launch Renewable Energy Projects In 7 Arab Countries
August 16, 2022

Israeli Secure Enterprise Browser Provider Raises $100M
August 15, 2022

Wiz Becomes World’s Fastest-Growing Software Company
August 15, 2022
Facebook comments